These data indicate an interesting concept that can be used for future research on potential targeted therapy in patients with BRCA1 mutated ovarian cancer [16] cAMP concentration in platinum-resistant cancer cells: OV81.2-CP10 and Aldhpos CP70 is significantly higher than in non-transformed cell lines. This evidence concerns the gene BRCA1 and ovarian carcinoma.